Zoetis (NYSE:ZTS) PT Lowered to $225.00 at HSBC

Zoetis (NYSE:ZTS) had its price objective lowered by research analysts at HSBC from $230.00 to $225.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HSBC’s price objective suggests a potential upside of 33.83% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. Stifel Nicolaus dropped their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Barclays dropped their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Piper Sandler restated an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Finally, The Goldman Sachs Group cut their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $211.75.

Zoetis Trading Up 1.9 %

Shares of Zoetis stock opened at $168.13 on Wednesday. The firm has a 50-day simple moving average of $166.94 and a two-hundred day simple moving average of $178.83. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a market cap of $76.72 billion, a P/E ratio of 32.40, a price-to-earnings-growth ratio of 2.57 and a beta of 0.86.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. Zoetis’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.31 EPS. As a group, equities analysts predict that Zoetis will post 5.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 363 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the sale, the executive vice president now directly owns 20,417 shares in the company, valued at $4,037,257.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 2,209 shares of company stock valued at $371,293 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zoetis

Hedge funds have recently modified their holdings of the company. Wintrust Investments LLC raised its stake in Zoetis by 2.1% during the first quarter. Wintrust Investments LLC now owns 8,281 shares of the company’s stock worth $1,401,000 after purchasing an additional 169 shares during the period. Nwam LLC increased its holdings in shares of Zoetis by 16.0% during the 1st quarter. Nwam LLC now owns 4,962 shares of the company’s stock worth $836,000 after buying an additional 684 shares during the last quarter. Gratus Wealth Advisors LLC raised its position in shares of Zoetis by 5.4% during the 1st quarter. Gratus Wealth Advisors LLC now owns 2,102 shares of the company’s stock valued at $356,000 after buying an additional 107 shares during the period. Great Lakes Retirement Inc. lifted its holdings in Zoetis by 4.2% in the first quarter. Great Lakes Retirement Inc. now owns 6,794 shares of the company’s stock valued at $1,150,000 after acquiring an additional 271 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC increased its stake in Zoetis by 16.0% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 4,643 shares of the company’s stock worth $786,000 after acquiring an additional 641 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.